drug
deoxycholic acid
Marketedupdated 3mo agoby Slayback Pharma LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying deoxycholic acid
- phase2A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
- N/AEvaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat
- phase3Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
- N/AEffectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat
- N/AEvaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas
- phase3A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
- phase3norUrsodeoxycholic Acid vs Placebo in PSC
- phase2Norursodeoxycholic Acid vs. Placebo in NASH
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 10, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Feb 17, 2032method-of-use (U-1940)US 12161653
- Mar 2, 2030formulationUS 105002143.5y
- Mar 2, 2030formulationUS 81015933.5y
- Mar 2, 2030formulationUS 83676493.5y
- Mar 2, 2030formulationUS 86530583.5y
- May 16, 2028compositionUS 82422941.7y
- Feb 21, 2028formulationUS 84611401.5y
- Feb 21, 2028formulationUS 85463671.5y
- Feb 21, 2028formulationUS 88837701.5y
- Feb 21, 2028formulationUS 95221551.5y
- Feb 21, 2028method-of-use (U-1940)US 96363491.5y
- Feb 21, 2028method-of-use (U-1940)US 99499861.5y
- Dec 10, 2027method-of-use (U-1690)US 76221301.3y
- Dec 10, 2027method-of-use (U-1690)US 77542301.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that